Filing Flows › Monte Rosa Therapeutics (GLUE) › Q2 2026 › vs Q2 2025
Monte Rosa Therapeutics (GLUE) Q2 2026 vs Q2 2025 (year over year)
Monte Rosa Therapeutics's revenue fell $14.2M (-61%) from $23.2M in Q2 2025 to $9.0M in Q2 2026.
Monte Rosa Therapeutics, Q2 2026: revenue $9.0M (-61% year over year), operating margin -547.8%, net loss $43.4M, operating cash flow −$44.1M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $9.0M | $23.2M | −$14.2M | -61% |
| Other income, net | $5.9M | $4.5M | $1.5M | +33% |
| Net loss | $43.4M | $12.3M | $31.1M | +253% |
| Costs & expenses | $58.3M | $39.9M | $18.4M | +46% |
| Operating costs | $58.1M | $38.7M | $19.4M | +50% |
| Income tax | $208K | $1.2M | −$991K | -83% |
| Research & development | $48.0M | $30.7M | $17.3M | +56% |
| General & admin | $10.1M | $8.1M | $2.0M | +25% |
| Operating cash sources | $52.7M | $42.4M | $10.3M | +24% |
| Depreciation & amortization | $2.6M | $2.7M | −$121K | -4% |
| Share-based compensation | $6.0M | $4.9M | $1.1M | +22% |
| Cash used in operations | $44.1M | $34.7M | $9.4M | +27% |
| Net loss absorbed | $43.4M | $12.3M | $31.1M | +253% |
| Working capital & other | $9.3M | $30.1M | −$20.8M | -69% |
Questions
How much did Monte Rosa Therapeutics's revenue grow year over year in Q2 2026?
Monte Rosa Therapeutics's revenue fell $14.2M (-61%) from $23.2M in Q2 2025 to $9.0M in Q2 2026.